455 related articles for article (PubMed ID: 28577209)
1. Improved diagnosis and prognostication of patients with pleural malignant mesothelioma using biomarkers in pleural effusions and peripheral blood samples - a short report.
Beije N; Kraan J; den Bakker MA; Maat APWM; van der Leest C; Cornelissen R; Van NM; Martens JWM; Aerts JGJV; Sleijfer S
Cell Oncol (Dordr); 2017 Oct; 40(5):511-519. PubMed ID: 28577209
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor cells (CTCs) in malignant pleural mesothelioma (MPM).
Yoneda K; Tanaka F; Kondo N; Hashimoto M; Takuwa T; Matsumoto S; Okumura Y; Tsubota N; Sato A; Tsujimura T; Kuribayashi K; Fukuoka K; Tabata C; Nakano T; Hasegawa S
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S472-80. PubMed ID: 24306661
[TBL] [Abstract][Full Text] [Related]
3. Detection of circulating tumor cells with a novel microfluidic system in malignant pleural mesothelioma.
Yoneda K; Kuwata T; Chikaishi Y; Mori M; Kanayama M; Takenaka M; Oka S; Hirai A; Imanishi N; Kuroda K; Ichiki Y; Ohnaga T; Tanaka F
Cancer Sci; 2019 Feb; 110(2):726-733. PubMed ID: 30499156
[TBL] [Abstract][Full Text] [Related]
4. Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue.
Hida T; Matsumoto S; Hamasaki M; Kawahara K; Tsujimura T; Hiroshima K; Kamei T; Taguchi K; Iwasaki A; Oda Y; Honda H; Nabeshima K
Cancer Sci; 2015 Nov; 106(11):1635-41. PubMed ID: 26291840
[TBL] [Abstract][Full Text] [Related]
5. Circulating endothelial cell (CEC) as a diagnostic and prognostic marker in malignant pleural mesothelioma (MPM).
Yoneda K; Tanaka F; Kondo N; Orui H; Hashimoto M; Takuwa T; Matsumoto S; Okumura Y; Tsubota N; Sato A; Tsujimura T; Kuribayashi K; Fukuoka K; Nakano T; Hasegawa S
Ann Surg Oncol; 2012 Dec; 19(13):4229-37. PubMed ID: 22825770
[TBL] [Abstract][Full Text] [Related]
6. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
[TBL] [Abstract][Full Text] [Related]
7. The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with malignant pleural mesothelioma.
Muraoka T; Soh J; Toyooka S; Aoe K; Fujimoto N; Hashida S; Maki Y; Tanaka N; Shien K; Furukawa M; Yamamoto H; Asano H; Tsukuda K; Kishimoto T; Otsuki T; Miyoshi S
Lung Cancer; 2013 Dec; 82(3):485-90. PubMed ID: 24168922
[TBL] [Abstract][Full Text] [Related]
8. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
[TBL] [Abstract][Full Text] [Related]
9. Tumor-specific genetic variants can be detected in circulating cell-free DNA of malignant pleural mesothelioma patients.
Hylebos M; Op de Beeck K; Pauwels P; Zwaenepoel K; van Meerbeeck JP; Van Camp G
Lung Cancer; 2018 Oct; 124():19-22. PubMed ID: 30268460
[TBL] [Abstract][Full Text] [Related]
10. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
[TBL] [Abstract][Full Text] [Related]
11. Detection of circulating tumour cells in peripheral blood of patients with malignant pleural mesothelioma.
Raphael J; Massard C; Gong IY; Farace F; Margery J; Billiot F; Hollebecque A; Besse B; Soria JC; Planchard D
Cancer Biomark; 2015; 15(2):151-6. PubMed ID: 25519011
[TBL] [Abstract][Full Text] [Related]
12. [Exploratory study on the detection of markers for diagnosing early-stage malignant mesothelioma].
Fukuoka K; Tanaka F; Tsujimura T; Hashimoto-Tamaoki T; Hasegawa S; Nakano T
Nihon Eiseigaku Zasshi; 2011 May; 66(3):553-7. PubMed ID: 21701086
[TBL] [Abstract][Full Text] [Related]
13. Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma.
Schneider MA; Muley T; Kahn NC; Warth A; Thomas M; Herth FJ; Dienemann H; Meister M
Oncotarget; 2016 Nov; 7(44):71285-71297. PubMed ID: 27713145
[TBL] [Abstract][Full Text] [Related]
14. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
Ferro P; Canessa PA; Battolla E; Dessanti P; Franceschini MC; Chiaffi L; Morabito A; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
Anticancer Res; 2013 Jun; 33(6):2707-13. PubMed ID: 23749930
[TBL] [Abstract][Full Text] [Related]
15. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
de Reyniès A; Jaurand MC; Renier A; Couchy G; Hysi I; Elarouci N; Galateau-Sallé F; Copin MC; Hofman P; Cazes A; Andujar P; Imbeaud S; Petel F; Pairon JC; Le Pimpec-Barthes F; Zucman-Rossi J; Jean D
Clin Cancer Res; 2014 Mar; 20(5):1323-34. PubMed ID: 24443521
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.
Yamada S; Tabata C; Tabata R; Fukuoka K; Nakano T
Clin Chem Lab Med; 2011 Oct; 49(10):1721-6. PubMed ID: 21692685
[TBL] [Abstract][Full Text] [Related]
17. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma.
Pass HI; Levin SM; Harbut MR; Melamed J; Chiriboga L; Donington J; Huflejt M; Carbone M; Chia D; Goodglick L; Goodman GE; Thornquist MD; Liu G; de Perrot M; Tsao MS; Goparaju C
N Engl J Med; 2012 Oct; 367(15):1417-27. PubMed ID: 23050525
[TBL] [Abstract][Full Text] [Related]
18. Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis.
Kirschner MB; Pulford E; Hoda MA; Rozsas A; Griggs K; Cheng YY; Edelman JJ; Kao SC; Hyland R; Dong Y; László V; Klikovits T; Vallely MP; Grusch M; Hegedus B; Dome B; Klepetko W; van Zandwijk N; Klebe S; Reid G
Br J Cancer; 2015 Sep; 113(6):963-9. PubMed ID: 26263483
[TBL] [Abstract][Full Text] [Related]
19. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - A multi-institutional study.
Hoda MA; Dong Y; Rozsas A; Klikovits T; Laszlo V; Ghanim B; Stockhammer P; Ozsvar J; Jakopovic M; Samarzija M; Brcic L; Bendek M; Szirtes I; Reid G; Kirschner MB; Kao SC; Opitz I; Weder W; Frauenfelder T; Nguyen-Kim TD; Aigner C; Klepetko W; van Zandwijk N; Berger W; Dome B; Grusch M; Hegedus B
Eur J Cancer; 2016 Aug; 63():64-73. PubMed ID: 27288871
[TBL] [Abstract][Full Text] [Related]
20. Circulating microRNAs found dysregulated in ex-exposed asbestos workers and pleural mesothelioma patients as potential new biomarkers.
Bononi I; Comar M; Puozzo A; Stendardo M; Boschetto P; Orecchia S; Libener R; Guaschino R; Pietrobon S; Ferracin M; Negrini M; Martini F; Bovenzi M; Tognon M
Oncotarget; 2016 Dec; 7(50):82700-82711. PubMed ID: 27716620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]